News Release

Whitepaper Describes Stroma Liquid Biopsy™ Cancer Serum Biomarker Panel

Methods to monitor and potentially modulate the systemic response to cancer, offer new avenues for early detection, personalized medicine and therapeutic modalities.

MONMOUTH JUNCTION, NJ , February 27, 2019 -- Biotech Support Group announced today that it has published a whitepaper describing Stroma Liquid Biopsy™, a pan-cancer biomarker panel of dysregulation derived from blood.

The title and download link is:

Stroma Liquid Biopsy™ - Blood-based biomarkers to monitor stromal conditioning in cancer. Published February, 2019.

http://www.biotechsupportgroup.com/v/vspfiles/templates/257/pdf/StromaLiquidBiopsyWhitepaper022519.pdf

The whitepaper describes that tumors are more than simply a collection of immortalized cells as the supporting microenvironments or stroma also contributes to pathogenesis. Because of this, tumor characterization cannot be fully characterized solely through the analyses of the tumor cell genome – the current emphasis of liquid biopsy platforms. So because tumors are more than just a mass of proliferating cells, cancer progression must take into consideration the influence of the multiple cell types and networks of proteins dynamically interacting in active tumorigenesis. These are not simply passive bystanders.

The unique significance of the Stroma Liquid Biopsy™ pan-cancer profile is that dysregulation in blood was categorically intertwined with the most rudimentary needs of cancer: space, nutrients and immune evasion. Moreover, the changes within the 13 biomarker panel all occur within an interdependent network of cascading proteolytic events. Because proteolysis is irreversible, all species of life have evolved molecular regulatory systems to control aberrancies. The most distinguished is a protease inhibitory family of regulators known as SERPINs. Although SERPINs circulate in a variety of functional on/off sub-forms, conventionally they are observed and reported in aggregate (i.e., ELISA). As a result, their influence on disease is missed. Using combined LC-MS peptide features and enzyme assay methods that directly assess SERPIN function, rather than antigen presentation, we now have evidence that there is an imbalance of functional SERPIN sub-forms in the cancer population relative to that of a normal population.

“As we now have patent pending m ethods to monitor the influence of an overlooked protein family – the SERPINs, we now have s a fundamentally new way to think about molecular dysregulation in blood from a cancer patient. As described in our whitepaper, new insights will be extracted into the opportunistic mechanisms that drive cancer pathogenesis and metastatic dissemination, and we advance how those might be unwound therapeutically to improve survival. Our next goal is for rigorous investigations into progressive disease and response to therapies with partners and collaborators. This will be our first step towards the ultimate goal of validating biomarkers useful in the clinic. We welcome inquiries to commercialize Stroma Liquid Biopsy™ for the many different applications it can serve including early detection, wellness and risk factor monitoring, oncology drug development and personalized therapy decisions, ” said Dr. Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

For business development inquires, contact:
Matt Kuruc 732-274-2866 , mkuruc@biotechsupportgroup.com

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com